Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized open-label multi-dose study of oral AND017 in lower-risk myelodysplastic syndrome
CTR20244586Phase 2Active
- Sponsor
- Ando Pharma
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of AND017 in myelodysplastic syndrome (MDS) (3 arms), sponsored by Ando Pharma. Primary endpoints: Safety and HI-E/RBC-TI responder rate. Started Mar 2025; status: active.
02
Drugs
AND017
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on CTR20244586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244586.